The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 dose escalation of XMT-1522, a novel HER2-targeting antibody-drug conjugate (ADC), in patients (pts) with HER2-expressing breast, lung and gastric tumors.
 
Erika Paige Hamilton
Consulting or Advisory Role - Cascadian Therapeutics (Inst); Flatiron Health; Genentech/Roche (Inst); Lilly (Inst); Pfizer (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); AstraZeneca (Inst); BerGenBio (Inst); Boehringer Ingelheim (Inst); Cascadian Therapeutics (Inst); Curis (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); Fujifilm (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Hutchison MediPharma (Inst); Immunomedics (Inst); Kadmon (Inst); Lilly (Inst); Lycera (Inst); Macrogenics (Inst); Mallinckrodt (Inst); MedImmune (Inst); Medivation (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Novartis (Inst); Nucana (Inst); OncoMed (Inst); Pfizer (Inst); PharmaMar (Inst); Radius Health (Inst); Rgenix (Inst); Stem CentRx (Inst); Syndax (Inst); Takeda (Inst); TapImmune Inc. (Inst); Tesaro (Inst); TetraLogic Pharmaceuticals (Inst); Verastem (Inst); Zymeworks (Inst)
 
Minal A. Barve
No Relationships to Disclose
 
Aditya Bardia
Consulting or Advisory Role - bioTheranostics; Genentech; Novartis; Pfizer; Spectrum Pharmaceuticals
 
Muralidhar Beeram
No Relationships to Disclose
 
Johanna C. Bendell
Research Funding - Abbott/AbbVie (Inst); Agios (Inst); Apexigen (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Five Prime Therapeutics (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Incyte (Inst); Ipsen (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Marshall Edwards (Inst); Merck (Inst); Merrimack (Inst); Mersana (Inst); Merus (Inst); Nektar (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Onyx (Inst); Pieris Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst); SynDevRx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TG Therapeutics (Inst); Tyrogenex (Inst)
 
Rebecca Mosher
Employment - Mersana
Stock and Other Ownership Interests - Mersana
 
Eric Hailman
Employment - Mersana
Stock and Other Ownership Interests - Mersana
 
Donald Alan Bergstrom
Employment - Mersana
Leadership - Mersana
Stock and Other Ownership Interests - Mersana
Patents, Royalties, Other Intellectual Property - Mersana
 
Howard A. Burris
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); FORMA Therapeutics (Inst); Janssen (Inst); MedImmune (Inst); Mersana (Inst); Novartis (Inst); Roche/Genentech (Inst); TG Therapeutics (Inst)
Research Funding - Abbvie (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); BioMed Valley Discoveries (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); CytomX Therapeutics (Inst); eFFECTOR Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Incyte (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); Millennium (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PTC Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tesaro (Inst); TG Therapeutics (Inst); Valent Technologies (Inst); Verastem (Inst); Vertex (Inst)
Expert Testimony - Novartis
 
Hatem Hussein Soliman
Consulting or Advisory Role - AstraZeneca; Celgene; Lilly; Novartis; Pfizer
Research Funding - Amgen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Lilly